Third death reported with a Sarepta gene therapy

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.

RNA therapy firm Avidity files $400m placement

Avidity Biosciences has filed a private placement worth around $400 million, seeking a cash infusion to help advance its pipeline of clinical-stage candidates that combine

Gene Therapy for Muscular Disorders

The ONLY digital meeting in this space!

Sarepta rebounds on data for limb-girdle muscular dystrophy ...

Understanding muscular dystrophy

Chris Anselmo, who has a rare form of muscular dystrophy, hopes to educate pharma on the patient journey and help new patients cope with a life-changing diagnosis.